Impax Laboratories, LLC clinical trials

Acquired by Amneal Pharmaceuticals, Inc., May 4, 2018 · source ↗

The registry lists 20 studies whose lead sponsor is Impax Laboratories, LLC. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 24, 2025.

Studies

Recruiting first, then most recently updated. Showing 20 of 20. All Amneal Pharmaceuticals, Inc. studies →

• A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's DiseaseRecruitingNCT06765668Phase 4

  Sponsor listed in the registry: Impax Laboratories, LLC · First submitted after Impax Laboratories, LLC became part of Amneal Pharmaceuticals, Inc.

• Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in AdolescentsCompletedNCT00617695Phase 3

  Sponsor listed in the registry: Impax Laboratories, LLC · First submitted before Impax Laboratories, LLC became part of Amneal Pharmaceuticals, Inc.

• A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy SubjectsCompletedNCT06161220Phase 1

  Sponsor listed in the registry: Impax Laboratories, LLC · First submitted after Impax Laboratories, LLC became part of Amneal Pharmaceuticals, Inc.

• Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor FluctuationsCompletedNCT03877510Phase 3

  Sponsor listed in the registry: Impax Laboratories, LLC · First submitted after Impax Laboratories, LLC became part of Amneal Pharmaceuticals, Inc.

• A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor FluctuationsCompletedNCT03670953Phase 3

  Sponsor listed in the registry: Impax Laboratories, LLC · First submitted after Impax Laboratories, LLC became part of Amneal Pharmaceuticals, Inc.

• A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's DiseaseCompletedNCT03007888Phase 2

  Sponsor listed in the registry: Impax Laboratories, LLC · First submitted before Impax Laboratories, LLC became part of Amneal Pharmaceuticals, Inc.

• Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLECompletedNCT03275922Phase 3

  Sponsor listed in the registry: Impax Laboratories, LLC · First submitted before Impax Laboratories, LLC became part of Amneal Pharmaceuticals, Inc.

• A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).CompletedNCT00974974Phase 3

  Sponsor listed in the registry: Impax Laboratories, LLC · First submitted before Impax Laboratories, LLC became part of Amneal Pharmaceuticals, Inc.

• A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-LevodopaCompletedNCT00869791Phase 2

  Sponsor listed in the registry: Impax Laboratories, LLC · First submitted before Impax Laboratories, LLC became part of Amneal Pharmaceuticals, Inc.

• An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's DiseaseCompletedNCT01096186Phase 3

  Sponsor listed in the registry: Impax Laboratories, LLC · First submitted before Impax Laboratories, LLC became part of Amneal Pharmaceuticals, Inc.

• Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety StudyCompletedNCT01411137Phase 3

  Sponsor listed in the registry: Impax Laboratories, LLC · First submitted before Impax Laboratories, LLC became part of Amneal Pharmaceuticals, Inc.

• IPX056 in Subjects With Established Spasticity Resulting From Multiple SclerosisCompletedNCT00488839Phase 3

  Sponsor listed in the registry: Impax Laboratories, LLC · First submitted before Impax Laboratories, LLC became part of Amneal Pharmaceuticals, Inc.

• A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's DiseaseCompletedNCT02271503Phase 2

  Sponsor listed in the registry: Impax Laboratories, LLC · First submitted before Impax Laboratories, LLC became part of Amneal Pharmaceuticals, Inc.

• A Study With IPX056 in Subjects With Spasticity Associated With Multiple SclerosisCompletedNCT00914290Phase 2

  Sponsor listed in the registry: Impax Laboratories, LLC · First submitted before Impax Laboratories, LLC became part of Amneal Pharmaceuticals, Inc.

• A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's DiseaseCompletedNCT00880620Phase 3

  Sponsor listed in the registry: Impax Laboratories, LLC · First submitted before Impax Laboratories, LLC became part of Amneal Pharmaceuticals, Inc.

• Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's DiseaseCompletedNCT00279825Phase 2

  Sponsor listed in the registry: Impax Laboratories, LLC · First submitted before Impax Laboratories, LLC became part of Amneal Pharmaceuticals, Inc.

• Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's DiseaseCompletedNCT00239564Phase 1/2

  Sponsor listed in the registry: Impax Laboratories, LLC · First submitted before Impax Laboratories, LLC became part of Amneal Pharmaceuticals, Inc.

• Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's DiseaseCompletedNCT00253084Phase 2

  Sponsor listed in the registry: Impax Laboratories, LLC · First submitted before Impax Laboratories, LLC became part of Amneal Pharmaceuticals, Inc.

• A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066CompletedNCT01130493Phase 3

  Sponsor listed in the registry: Impax Laboratories, LLC · First submitted before Impax Laboratories, LLC became part of Amneal Pharmaceuticals, Inc.

• Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)CompletedNCT01521663Phase 2

  Sponsor listed in the registry: Impax Laboratories, LLC · First submitted before Impax Laboratories, LLC became part of Amneal Pharmaceuticals, Inc.